Advertisement

Topics

RhoVac AB looks to begin Phase 2b trials with prostate cancer drug in 2Q 2019

05:21 EST 11 Jan 2019 | Proactive Investors

RhoVac AB (OMX:RHOVAC) CEO Anders Ljungqvist sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The Sweden and Denmark-based immuno-oncology company is developing a therapeutic cancer vaccine that targets metastatic cancer cells.  The company's cancer vaccine product RV001, in clinical trial, recognizes metastatic cancer cells and stimulates the immune system to target them.

Original Article: RhoVac AB looks to begin Phase 2b trials with prostate cancer drug in 2Q 2019

NEXT ARTICLE

More From BioPortfolio on "RhoVac AB looks to begin Phase 2b trials with prostate cancer drug in 2Q 2019"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...